Form 4: Pacira SVP Riker Granted 19,273 RSUs

Pacira BioSciences, Inc. Senior Vice President of Finance, Lauren Riker, was granted 19,273 restricted stock units, vesting over four years.

Summary

• Lauren Riker, Senior Vice President of Finance at Pacira BioSciences, Inc. (PCRX), acquired 19,273 shares of common stock.
• The acquisition occurred on February 11, 2026, at a price of $0 per share.
• These shares represent restricted stock units (RSUs) that will vest in four equal annual installments.
• The first vesting date for these RSUs is scheduled for February 15, 2027.
• Vesting is contingent upon Ms. Riker's continuous service with the issuer as of each vesting date.
• Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
• Following this transaction, Ms. Riker beneficially owns a total of 71,586.242 shares of common stock.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development for corporate governance and management alignment, as RSU grants incentivize long-term performance and retention, which is generally favorable for shareholders.

Positives

• The grant of restricted stock units aligns the Senior Vice President of Finance's interests with long-term shareholder value.
• The multi-year vesting schedule incentivizes executive retention and sustained performance.

Negatives

• The acquired shares are restricted stock units and do not represent immediate, unrestricted ownership.
• The value of the grant is contingent on future stock performance and Ms. Riker's continued employment.

Risks

• The vesting of the 19,273 restricted stock units is contingent on Lauren Riker's continuous service with Pacira BioSciences, Inc. as of each vesting date.
• The ultimate value of the RSUs is subject to the future market price of Pacira BioSciences, Inc. common stock.

Future Outlook

The grant of restricted stock units with a multi-year vesting schedule indicates a commitment to retaining key management and aligning their incentives with the company's long-term performance through at least February 2030, assuming continuous service.

Industry Context

StockSavvy.ai notes that RSU grants are a common form of executive compensation in the biotechnology and pharmaceutical industries. This practice is designed to align the interests of management with those of shareholders by tying a significant portion of executive pay to the company's stock performance and long-term value creation, while also serving as a retention tool.

Comparison to Industry Standards

• The grant of restricted stock units with a four-year annual vesting schedule is a standard practice for executive compensation across various industries, including biotech, for companies like Amgen, Gilead Sciences, and Biogen. This structure is widely used to incentivize long-term performance and executive retention.
• The $0 acquisition price for RSUs is typical, as these are compensatory grants rather than open market purchases, consistent with compensation plans at peer companies.

Corporate Governance

Stakeholder Impact

• Shareholders: The RSU grant aligns management's financial interests with the company's long-term stock performance, potentially benefiting shareholders through sustained value creation.
• Employees (specifically Lauren Riker): The grant provides a significant equity incentive, enhancing retention and motivation for the Senior Vice President of Finance.

Next Steps

• The restricted stock units will begin vesting in four equal annual installments starting on February 15, 2027, contingent on continuous service.

Key Dates

Recommendation

This Form 4 reports a routine restricted stock unit grant to a Senior Vice President, which is a standard component of executive compensation. It indicates continued management alignment but does not provide new material operational or financial information that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as it reflects no significant new catalysts for price movement based solely on this filing.

Keywords

Pacira BioSciences, PCRX, Restricted Stock Units, RSU, Insider Transaction, Executive Compensation, Lauren Riker, Form 4